EGFR alterations, particularly amplifications, generally predict worse survival in astrocytomas and glioblastomas, while PTEN alterations (mutations or deletions) are linked to poor prognosis specifically in GBM [42, 43]. This evidence concerns the gene EGFR and glioblastoma.